- Karminomycin
- Karminomycin hydrochloride
- 394730-60-0Boceprevir
- 394734-77-11,2-Pyrrolidinedicarboxylicacid, 4-cyclohexyl-, 1-(1,1-dimethylethyl) ester, (2S,4S)-
- 394735-17-2Cyclobutanepropanoicacid, a-amino-, ethyl ester
- 394735-22-9(2-Carbamoyl-1-cyclobutylmethyl-2-hydroxy-ethyl)-carbamic acid tert-butyl ester
- 39475-55-3diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxy-λ5-phosphane
- 3947-62-4β-D-Glucopyranose,2,3,4,6-tetraacetate
- 39478-78-9Benzenamine,5-bromo-2-methyl-
- 39482-87-6Silanamine,N-[dimethyl(3,3,3-trifluoropropyl)silyl]-1,1-dimethyl-1-(3,3,3-trifluoropropyl)-
- 39483-74-4Bismuthine, trichloro-,monohydrate (9CI)
- 39489-77-5Phenol,2,4-dichloro-5-nitro-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Karminomycin |
EINECS | N/A |
| CAS No. | 39472-31-6 | Density | 1.63g/cm3 |
| PSA | 196.84000 | LogP | 1.42620 |
| Solubility | N/A | Melting Point |
191-192°C |
| Formula | C26H27NO10 | Boiling Point | 750.6°Cat760mmHg |
| Molecular Weight | 513.4933 | Flash Point | 407.7°C |
| Transport Information | N/A | Appearance | N/A |
| Safety | Poison by ingestion, intravenous, intraperitoneal, and subcutaneous routes. Human systemic effects by intravenous route: anorexia, hallucinations and distorted perceptions, thrombosis, nausea or vomiting, fatty liver degeneration, impaired liver function, endocrine changes, and leukopenia (reduced white blood cell count). An experimental teratogen. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits acrid smoke and fumes. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Carminomycin;CARMINOMYCIN,CARUBICIN; |
Karminomycin Chemical Properties
IUPAC: (7S,9S)-9-Acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4,6,9,11-tetrahydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Karminomycin with CAS NO.of 39472-31-6 is also called for Carubicin ; CCRIS 961 ; Carminomycin ; STOCK1N-41435 ; AIDS-166741 ; CID443831 ; NCGC00159344-02 ; C12432 ; O-Demethyldaunomycin and so on.
Molecular Weight: 513.49
Molecular Formula: C26H27NO10
ACD/LogP: 3.54
ACD/LogD (pH 5.5): 0.78
ACD/LogD (pH 7.4): 1.11
ACD/BCF (pH 5.5): 1
ACD/BCF (pH 7.4): 1.08
ACD/KOC (pH 5.5): 3.49
ACD/KOC (pH 7.4): 7.49
H bond acceptors: 11
H bond donors: 7
Freely Rotating Bonds: 9
Heavy Atom Count: 37
Formal Charge: 0
Complexity: 944
Isotope Atom Count: 0
Defined Atom StereoCenter Count: 6
Undefined Atom StereoCenter Count: 0
Defined Bond StereoCenter Count: 0
Undefined Bond StereoCenter Count: 0
Covalently-Bonded Unit Count: 1
Index of Refraction: 1.726
Molar Refractivity: 125.14 cm3
Molar Volume: 314.6 cm3
Surface Tension: 99.8 dyne/cm
Density: 1.63 g/cm3
Flash Point: 407.7°C
Enthalpy of Vaporization: 114.8 kJ/mol
Boiling Point: 750.6°C at 760 mmHg
Vapour Pressure: 1.14E-23 mmHg at 25°C
The molecular structure of Karminomycin with CAS NO.of 39472-31-6:
Karminomycin Uses
Karminomycin (CAS NO.39472-31-6) is used as antineoplastic agent.
Karminomycin Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | oral | 2700ug/kg (2.7mg/kg) | Cancer Treatment Reports. Vol. 63, Pg. 899, 1979. | |
| dog | LDLo | intravenous | 600ug/kg (0.6mg/kg) | Cancer Treatment Reports. Vol. 63, Pg. 899, 1979. | |
| human | TDLo | intravenous | 12mg/kg/5D (12mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: LEUKOPENIA | Cancer Treatment Reports. Vol. 61, Pg. 1705, 1977. |
| mammal (species unspecified) | LD50 | intraperitoneal | 1300ug/kg (1.3mg/kg) | Antibiotiki. Vol. 29, Pg. 748, 1984. | |
| man | TDLo | intravenous | 1071ug/kg/17D (1.071mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" VASCULAR: THROMBOSIS DISTANT FROM INJECTION SITE GASTROINTESTINAL: NAUSEA OR VOMITING | Voprosy Onkologii. Problems of Oncology. For English translation, see PONCAU. Vol. 25(2), Pg. 63, 1979. |
| monkey | LD50 | oral | 288mg/kg (288mg/kg) | BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING | Drug and Chemical Toxicology. Vol. 4, Pg. 383, 1981. |
| mouse | LD50 | intraperitoneal | 960ug/kg (0.96mg/kg) | Antibiotiki. Vol. 29, Pg. 437, 1984. | |
| mouse | LD50 | intravenous | 3200ug/kg (3.2mg/kg) | Antibiotiki. Vol. 23, Pg. 1005, 1978. | |
| mouse | LD50 | oral | 7300ug/kg (7.3mg/kg) | Cancer Treatment Reports. Vol. 61, Pg. 1705, 1977. | |
| mouse | LD50 | subcutaneous | 2500ug/kg (2.5mg/kg) | Antibiotiki. Vol. 21, Pg. 1030, 1976. | |
| rat | LD50 | intraperitoneal | 1550ug/kg (1.55mg/kg) | LIVER: FATTY LIVER DEGERATION LIVER: LIVER FUNCTION TESTS IMPAIRED ENDOCRINE: OTHER CHANGES | Antibiotiki. Vol. 24, Pg. 218, 1979. |
| rat | LD50 | intravenous | 1600ug/kg (1.6mg/kg) | Antibiotiki. Vol. 23, Pg. 1005, 1978. | |
| rat | LD50 | oral | 23mg/kg (23mg/kg) | Antibiotiki. Vol. 21, Pg. 904, 1976. | |
| rat | LD50 | subcutaneous | 4366ug/kg (4.366mg/kg) | Drug and Chemical Toxicology. Vol. 4, Pg. 383, 1981. |
Karminomycin Safety Profile
Poison by ingestion, intravenous, intraperitoneal, and subcutaneous routes. Human systemic effects by intravenous route: anorexia, hallucinations and distorted perceptions, thrombosis, nausea or vomiting, fatty liver degeneration, impaired liver function, endocrine changes, and leukopenia (reduced white blood cell count). An experimental teratogen. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits acrid smoke and fumes.
What can I do for you?
Get Best Price
